Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to $1.7 million.

  • Ptc Therapeutics' Current Deferred Revenue changed N/A to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year change of. This contributed to the annual value of $5.5 million for FY2024, which is 58726.59% up from last year.
  • According to the latest figures from Q3 2025, Ptc Therapeutics' Current Deferred Revenue is $1.7 million.
  • In the past 5 years, Ptc Therapeutics' Current Deferred Revenue ranged from a high of $12.8 million in Q1 2025 and a low of $214000.0 during Q1 2023
  • In the last 5 years, Ptc Therapeutics' Current Deferred Revenue had a median value of $1.7 million in 2025 and averaged $3.9 million.
  • Per our database at Business Quant, Ptc Therapeutics' Current Deferred Revenue tumbled by 8173.08% in 2021 and then surged by 58726.59% in 2024.
  • Quarter analysis of 5 years shows Ptc Therapeutics' Current Deferred Revenue stood at $1.9 million in 2021, then dropped by 28.89% to $1.4 million in 2022, then plummeted by 40.71% to $801000.0 in 2023, then soared by 587.27% to $5.5 million in 2024, then plummeted by 69.28% to $1.7 million in 2025.
  • Its Current Deferred Revenue was $1.7 million in Q3 2025, compared to $9.8 million in Q2 2025 and $12.8 million in Q1 2025.